In total, the company has already received Orphan drug designation for vaccines for pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia.
BioSante Pharma president and CEO Stephen Simes said they continue to develop their vaccine portfolio in cooperation with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
"Clinical trials of our cancer vaccines are being conducted to treat leukemia, breast cancer, and pancreatic cancer, among other cancer types," Simes said.